Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.

PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC). PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective tria...

Full description

Bibliographic Details
Main Authors: Brunner, T, Eccles, C
Format: Journal article
Language:English
Published: 2010
_version_ 1797078060109922304
author Brunner, T
Eccles, C
author_facet Brunner, T
Eccles, C
author_sort Brunner, T
collection OXFORD
description PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC). PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials. Additionally, publications on the technical progress of radiotherapy in or close to the liver were analysed. RESULTS: most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year. Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis. Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection. However, data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease. For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice. But recent SEER analyses show that radiotherapy prolongs survival, relieves symptoms and contributes to biliary decompression and should be regarded as the new standard. Novel technical advances in radiotherapy may allow for dose-escalation and could significantly improve outcome for patients with cholangiocarcinoma. CONCLUSION: both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials. Progress is less pronounced in chemotherapy.
first_indexed 2024-03-07T00:27:02Z
format Journal article
id oxford-uuid:7e7c64a4-1838-4904-9808-53689b639a79
institution University of Oxford
language English
last_indexed 2024-03-07T00:27:02Z
publishDate 2010
record_format dspace
spelling oxford-uuid:7e7c64a4-1838-4904-9808-53689b639a792022-03-26T21:10:26ZRadiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7e7c64a4-1838-4904-9808-53689b639a79EnglishSymplectic Elements at Oxford2010Brunner, TEccles, CPURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC). PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials. Additionally, publications on the technical progress of radiotherapy in or close to the liver were analysed. RESULTS: most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year. Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis. Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection. However, data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease. For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice. But recent SEER analyses show that radiotherapy prolongs survival, relieves symptoms and contributes to biliary decompression and should be regarded as the new standard. Novel technical advances in radiotherapy may allow for dose-escalation and could significantly improve outcome for patients with cholangiocarcinoma. CONCLUSION: both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials. Progress is less pronounced in chemotherapy.
spellingShingle Brunner, T
Eccles, C
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title_full Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title_fullStr Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title_full_unstemmed Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title_short Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
title_sort radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma
work_keys_str_mv AT brunnert radiotherapyandchemotherapyastherapeuticstrategiesinextrahepaticbiliaryductcarcinoma
AT ecclesc radiotherapyandchemotherapyastherapeuticstrategiesinextrahepaticbiliaryductcarcinoma